Metastatic clear cell renal cell carcinoma to the adrenal gland without an identifiable primary tumor

2011 ◽  
Vol 19 (1) ◽  
pp. 92-93 ◽  
Author(s):  
Matthew T Johnson ◽  
Robert R Bahnson ◽  
Debra L Zynger
Keyword(s):  
Renal Cell Carcinoma ◽  
Adrenal Gland ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor

BMC Urology ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Jeanette E. Eckel-Passow ◽  
Daniel J. Serie ◽  
John C. Cheville ◽  
Thai H. Ho ◽  
Payal Kapur ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Tumor Heterogeneity ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Carcinoma Tumor

scholarly journals Prognostic Value of The Ratio of Maximum To Minimum Diameter of Primary Tumor In Metastatic Clear Cell Renal Cell Carcinoma

2022 ◽  
Author(s):  
Hongzhe Shi ◽  
Chuanzhen Cao ◽  
Li Wen ◽  
Lianyu Zhang ◽  
Jin Zhang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Risk Score ◽  
Primary Tumor ◽  
Renal Cell ◽  
Prognostic Value ◽  
Tumor Necrosis ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

Abstract Background: Several models and markers were developed and found to predict outcome of advanced renal cell carcinoma. This study aimed to evaluate the prognostic value of the ratio of maximum to minimum tumor diameter (ROD) in metastatic clear cell renal cell carcinoma (mccRCC).Methods: Patients with mccRCC (n=213) treated with sunitinib from January 2008 to December 2018 were identified. Cut-off value for ROD was determined using receiver operating characteristic. Patients with different ROD scores were grouped and evaluated. Survival outcomes were estimated by Kaplan-Meier method.Results: The optimal ROD cutoff value of 1.34 was determined for progression free survival (PFS) and overall survival (OS). Patients in ROD≥1.34 group had shorter PFS (9.6 versus 17.7 months, p<0.001) and OS (25.5 versus 32.6 months, p<0.001) than patients in ROD<1.34 group. After adjustment for other factors, multivariate analysis showed ROD≥1.34 was an independent prognostic factor for PFS (p<0.001) and OS (p=0.006). Patients in ROD³1.34 group presented higher proportions of T3/4 stage (92.9% versus 7.1%, p=0.012), WHO/ISUP grade III/IV (72.0% versus 28.0%, p=0.010), tumor necrosis (71.0% versus 29.0%, p=0.039), sarcomatoid differentiation (79.1% versus 20.9%, p=0.007), poor MSKCC risk score (78.4% versus 21.6%, p<0.001) and poor IMDC risk score (74.4% versus 25.6%, p<0.001) than ROD<1.34 group.Conclusion: Primary tumor with higher ROD was an independently prognostic factor for both PFS and OS in patients with mccRCC who received targeted therapy. Higher ROD was also associated with high T stage, high WHO/ISUP grade, sarcomatoid features, tumor necrosis, poor MSKCC and IMDC risk score.

Survival of patients with papillary type II renal cell carcinoma treated with tyrosine-kinase inhibitors: A comparison with clear cell histologies.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 511-511 ◽  
Author(s):  
Jozefina Casuscelli ◽  
Alexander Buchner ◽  
Bernadett Szabados ◽  
Christian G. Stief ◽  
Michael D. Staehler
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Poor Prognosis ◽  
Kinase Inhibitors ◽  
Clear Cell ◽  
Type Ii ◽  
Cell Renal Cell Carcinoma ◽  
Papillary Type

511 Background: The sequential use of Tyrosine-kinase inhibitors leads to a longer survival in patients with clear-cell renal cell carcinoma (ccRCC). However to-date there is little data available on the survival of patients with non-clear-cell RCC treated with TKI. We focused on papillary type II renal cell carcinoma (papIIRCC) and assessed the outcome of our patients with metastatic disease on systemic treatment. The outcome was compared with our patients with clear cell histology. Methods: Patients with histologic evidence of papillary type II renal cell carcinoma or clear cell renal cell carcinoma were treated with single agent sunitinib or sorafenib. Progression free survival (PFS) and overall survival (OS) were analyzed with Kaplan-Meier curves. Patients were identified from an institutional database and had to have a follow up of ≥2 years. Subgroup analyses were performed to determine the influence of primary tumor stage and cell differentiation on PFS and OS. Results: 18 patients with papIIRCC received sunitinib (16) or sorafenib (2) while 166 patients with ccRCC were treated with sunitinib (78%) or sorafenib (22%). Median PFS for papIIRCC is 8.9 mos, for ccRCC it is 11 mos. OS for papIIRCC is 15 mos, while ccRCC show an OS of 32 mos. The same tendency for longer PFS and OS is seen in ccRCC patients with low primary tumor grade and highly differentiated carcinomas, whereas large tumors and low differentiation determine a poor prognosis in both groups. Conclusions: Most papIIRCC patients have a poor outcome and shorter PFS than ccRCC on the same therapy. They benefit from the TKI therapy, but the survival is clearly reduced compared with ccRCC patients. This may be due to the poor prognosis of the papillary type II histology, but the assumption is that the administered therapy is not conceived for this type of RCC. Future studies are required to determine the optimal therapy for papillary type II renal cell cancer.

scholarly journals Mutation Profile Variability in the Primary Tumor and Multiple Pulmonary Metastases of Clear Cell Renal Cell Carcinoma. A Review of the Literature and Analysis of Four Metastatic Cases

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5906
Author(s):  
Kristyna Prochazkova ◽  
Nikola Ptakova ◽  
Reza Alaghehbandan ◽  
Sean R. Williamson ◽  
Tomáš Vaněček ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Clear Cell ◽  
Pulmonary Metastases ◽  
Published Data ◽  
Cell Renal Cell Carcinoma ◽  
Primary Tumors ◽  
Mutation Profile

(1) Background: There are limited data concerning inter-tumoral and inter-metastatic heterogeneity in clear cell renal cell carcinoma (CCRCC). The aim of our study was to review published data and to examine mutation profile variability in primary and multiple pulmonary metastases (PMs) in our cohort of four patients with metastatic CCRCC. (2) Methods: Four patients were enrolled in this study. The clinical characteristics, types of surgeries, histopathologic results, immunohistochemical and genetic evaluations of corresponding primary tumor and PMs, and follow-up data were recorded. (3) Results: In our series, the most commonly mutated genes were those in the canonically dysregulated VHL pathway, which were detected in both primary tumors and corresponding metastasis. There were genetic profile differences between primary and metastatic tumors, as well as among particular metastases in one patient. (4) Conclusions: CCRCC shows heterogeneity between the primary tumor and its metastasis. Such mutational changes may be responsible for suboptimal treatment outcomes in targeted therapy settings.

638: Macroscopic Tumor Necrosis is a Prognostic Indicator for Non-Metastatic Clear Cell Renal Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 214-214
Author(s):  
Sung Kyu Hong ◽  
Byung Kyu Han ◽  
In Ho Chang ◽  
June Hyun Han ◽  
Ji Hyung Yu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Necrosis ◽  
Clear Cell ◽  
Prognostic Indicator ◽  
Cell Renal Cell Carcinoma ◽  
Macroscopic Tumor

Rare localization of renal cell carcinoma metastases in the paranasal sinuses and breast: a case report

2019 ◽  
Vol 22 (6) ◽  
pp. 13-22
Author(s):  
E. V. Kryaneva ◽  
N. A. Rubtsova ◽  
A. V. Levshakova ◽  
A. I. Khalimon ◽  
A. V. Leontyev ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paranasal Sinuses ◽  
Renal Cell ◽  
Clinical Case ◽  
Clear Cell ◽  
Malignant Tumors ◽  
Metastatic Potential ◽  
Cell Renal Cell Carcinoma ◽  
Metastatic Lesions

This article presents a clinical case demonsratinga high metastatic potential of clear cell renal cell carcinoma combined with atypical metastases to breast and paranasal sinuses. The prevalence of metastatic lesions to the breast and paranasal sinuses in various malignant tumors depending on their morphological forms is analyzed. The authors present an analysis of data published for the last 30 years. The optimal diagnostic algorithms to detect the progression of renal cell carcinoma and to evaluate the effectiveness of the treatment are considered.

Sign in / Sign up

Export Citation Format

Share Document